COVID-19
BioSpace takes a look at the annual compensation for the chief executive officers of vaccine developers.
There continue to be studies and trials related to vaccines and drugs against COVID-19. Here’s a look.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
The fear caused by COVID-19 provides an “in” for fraudsters to exploit thousands of Americans by posing as biotech companies.
Vaccine makers are working to create boosters or modify their existing vaccines to better respond to the variants.
A recent study from Ben-Gurion University of the Negev (BGU) found that isolated molecules from probiotic-rich dairy products could have potential as novel drug candidates for fighting against pathogenic bacteria and treating inflammatory diseases.
Eli Lilly and Company and Incyte announced today that their Phase III COV-BARRIER study of Olumiant (baricitinib) plus standard of care (SoC) compared to placebo plus SoC failed to hit statistical significance against COVID-19 for its primary endpoint.
The landscape may begin to become clearer as real-time research continues to emerge about the long-term effects of COVID-19 infection.
The $3.1 million NCATS grant will help the company test SPI-1005 in two trials, both OK’d by the U.S. Food and Drug Administration (FDA) last August.
Throughout 2020, the U.S. government spent billions of dollars to help finance the development of COVID-19 vaccines and therapeutics. Now, shareholders of the companies that received this financing are eager to see how those public funds will impact the pricing of these treatments.
PRESS RELEASES